Recall Register

Drug recall: Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva…

Class III FDA enforcement event 91958. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Teva Pharmaceuticals USA Inc started this drug recall on 27 Mar 2023. The firm address in the FDA record is in Parsippany, NJ. FDA put the recall in Class III. FDA event 91958 has 1 product record. The first FDA enforcement report date is 12 Apr 2023. The record gives the status Terminated, with the termination date 23 Aug 2023.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

USA Nationwide

Recalling firm

Teva Pharmaceuticals USA Inc, Parsippany, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 91958: product records
Recall numberProductQuantityClassStatusReport date
D-0510-2023Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-193,772 cartonsClass IIITerminated12 Apr 2023

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2023
281
Share of these events in Class III
26%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
60

Other events of the firm

Other FDA enforcement events of Teva Pharmaceuticals USA Inc
InitiatedProduct (first record)TypeClassRecords
24 Aug 2026traZODone Hydrochloride Tablets, USP, 50 mg, Rx only, 100 Tablets, Manufactured in Croatia By: Pliva Hrvatska d.o.o, ZagDrugClass II1
24 Apr 2026Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mLDrugClass II1
6 Apr 2026Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packsDrugClass II1
19 Mar 2026Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, ManufactDrugClass II3
17 Mar 2026Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial in Kit, Rx onlDrugClass II3
29 Jan 2026Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: 45963-709-11) and 1,000 tablets bottles DrugClass II4
12 Jan 2026Isotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack, Manufactured for: Teva Pharmaceuticals USA, Inc.DrugClass II2
7 Nov 2025Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, Rx only, Manufactured by: ActaviDrugClass III1
13 Oct 2025Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx oDrugClass II1
7 Oct 2025Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 194DrugClass II3

Teva Pharmaceuticals USA Inc: all 60 events

Official channels

Cite this page

Recall Register. FDA enforcement event 91958. https://recallregister.com/fda/iii/91958/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: USA Nationwide
What quantity of product is in FDA event 91958?
The FDA record gives this quantity: 3,772 cartons
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2023 have the same class?
26% of the 281 drug events that started in 2023 are in Class III.